Your browser is no longer supported. Please, upgrade your browser.
Settings
ASLN ASLAN Pharmaceuticals Limited daily Stock Chart
ASLN [NASD]
ASLAN Pharmaceuticals Limited
Index- P/E- EPS (ttm)-1.17 Insider Own- Shs Outstand160.25M Perf Week0.83%
Market Cap581.70M Forward P/E- EPS next Y-0.76 Insider Trans- Shs Float28.14M Perf Month0.83%
Income- PEG- EPS next Q-0.20 Inst Own9.35% Short Float0.00% Perf Quarter-16.17%
Sales- P/S- EPS this Y85.70% Inst Trans- Short Ratio0.10 Perf Half Y-16.55%
Book/sh0.82 P/B4.43 EPS next Y-280.00% ROA- Target Price7.63 Perf Year-58.51%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.51 - 9.18 Perf YTD0.83%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.55% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low40.64% ATR0.27
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)49.23 Volatility10.37% 8.28%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.65 Prev Close3.63
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume10.79K Price3.53
Recom- SMA202.36% SMA50-5.12% SMA200-25.79% Volume1,711 Change-2.75%
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
Jun-04-19 08:00AM  ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis GlobeNewswire
May-31-19 03:15AM  ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL GlobeNewswire -10.19%
May-10-19 04:15AM  ASLAN Pharmaceuticals Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer GlobeNewswire
May-06-19 09:00AM  ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why Zacks
Apr-29-19 05:02AM  ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Mar-29-19 12:13PM  Top Ranked Momentum Stocks to Buy for March 29th Zacks
05:50AM  ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis GlobeNewswire
Mar-28-19 10:41AM  Top Ranked Momentum Stocks to Buy for March 28th Zacks
Mar-22-19 07:25AM  ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire -5.71%
Mar-11-19 03:00AM  ASLAN Pharmaceuticals Signs New Agreement With Biogenetics for Commercialisation of ASLAN003 in South Korea GlobeNewswire
Feb-26-19 05:35PM  ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea GlobeNewswire
Jan-29-19 05:40PM  ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring GlobeNewswire
Jan-23-19 01:35AM  ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines GlobeNewswire
Jan-14-19 06:34PM  [$$] Aslan Reports Positive Data From Study Combining Its Drug With Chemotherapy The Wall Street Journal
05:44PM  ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI GlobeNewswire
09:46AM  ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study Zacks
Jan-13-19 05:30PM  ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer GlobeNewswire
Jan-04-19 02:00AM  ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period GlobeNewswire
Jan-02-19 03:48AM  ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule GlobeNewswire +15.28%
Dec-02-18 12:00PM  New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia GlobeNewswire
Nov-27-18 04:47AM  ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium GlobeNewswire
Nov-20-18 05:00AM  Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-08-18 06:05AM  ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-18 10:20AM  ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting GlobeNewswire
Oct-30-18 03:54AM  ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director GlobeNewswire
Oct-22-18 07:00AM  New Data Presented on ASLANs varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients GlobeNewswire
Oct-17-18 12:31PM  ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis GlobeNewswire
Oct-09-18 06:15AM  ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress GlobeNewswire
Sep-21-18 04:00AM  ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting GlobeNewswire
Sep-17-18 06:58AM  ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China GlobeNewswire
Sep-04-18 02:47AM  ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-20-18 02:49AM  ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia GlobeNewswire
Aug-10-18 08:19AM  ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer GlobeNewswire
Aug-06-18 04:05AM  ASLAN Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-03-18 04:01AM  ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004 GlobeNewswire
May-30-18 01:47PM  Analysts Roar Praise For Aslan, But Leerink More Tepid Benzinga +34.45%
08:35AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
May-17-18 02:25AM  ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO GlobeNewswire
ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical company in the United States. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor (HER), inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4, as well as gastric cancer. Its Varlitinib is currently being studied in a pivotal clinical trial for biliary tract cancer. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. Further, it develops ASLAN005, an antibody that is in preclinical development targeting recepteur d'origine nantais, an immune checkpoint inhibitor. The company has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has licensing agreement with Array BioPharma, Bristol-Myers Squibb, Almirall, CSL Limited, Hyundai Pharm Co., Ltd., Exploit Technologies Pte Ltd., and BioGenetics Co. Ltd.; and licensing and research collaboration agreement with Nanyang Technological University. The company was founded in 2010 and is headquartered in Singapore.